Clinical trials: Olanzapine
Bipolar Disorder
Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression
The purpose of this study is to assess olanzapine/fluoxetine combination and lamotrigine comparative efficacy, safety and tolerability in acute and longer term treatment of bipolar depression.
- Trial name
- NCT00485771
- Testing
- Olanzapine, Fluoxetine, Lamotrigine
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- Eli Lilly and Company
Misuse, Opioid
Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial
To learn about the effectiveness of taking the antipsychotic medication olanzapine to help lower opioid craving.
- Trial name
- NCT06200181
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Schizophrenia, Schizoaffective Disorder
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
- Trial name
- NCT03568500
- Testing
- Digital Medicine System, Aripiprazole, Olanzapine
- Where
- 5 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Dementia
Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD
The aim of this study is to discontinue antipsychotics and antidepressants, and to study its effect on Behavioural- and Psychological Symptoms in Dementia (BPSD).
- Trial name
- NCT00433121
- Testing
- Risperidone, Olanzapine, Haloperidole
- Where
- Norway
- Volunteers
- 24 people
- Sponsor
- Sykehuset Innlandet HF
Healthy
Fasting Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg
The objective of this study was to investigate the bioequivalence of Mylan's olanzapine 5 mg tablets to Eli Lilly's Zyprexa® 5 mg tablets following a single, oral 5 mg (1 x 5 mg) dose administered under fasting conditions.
- Trial name
- NCT00648921
- Testing
- Olanzapine Tablets 5 mg, Zyprexa® Tablets 5 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Pharmacokinetics
Fasted Bioequivalence Study of 2 Olanzapine Film-coated Tablets, 5 mg, in Healthy, Adult Male and Female Subjects.
This study was designed to assess the bioequivalence of Olanzapine tablets of two different manufacturers and to investigate the safety and tolerability of Olanzapine tablets of two different manufacturers.
- Trial name
- NCT05123976
- Testing
- Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine), Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V)
- Where
- Czechia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Joint Stock Company "Farmak"
Schizophrenia
Alleviating the Metabolic Side Effects of Antipsychotic Medications
The use of antipsychotic medications has increased over the past decade. While more recently developed medications are improved with regards to extrapyramidal side effects, the use of atypical antipsychotics has been associated…
- Trial name
- NCT01567124
- Testing
- Moxonidine
- Where
- 4 sites in Australia
- Sponsor
- Baker Heart and Diabetes Institute
Obsessive-Compulsive Disorder
Treatment of Obsessive-Compulsive Disorder
The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics).
- Trial name
- NCT00000373
- Testing
- olanzapine + fluoxetine
- Where
- 2 sites in United States
- Volunteers
- 74 people
- Sponsor
- University of Florida
Schizophrenia; Psychosis, Metabolic Syndrome
Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients
Fute (Flupentixol) combined with MARTAs (Multiple-Acting Receptor Targeted Antipsychotics) drugs has its clinical efficacy toward positive symptoms and might reduce the metabolic syndrome-related factors in patients.
- Conditions
- Schizophrenia; Psychosis, Metabolic Syndrome, Flupentixol, Antipsychotic Agents
- Trial name
- NCT04898270
- Testing
- Flupentixol, Multi-acting receptor-targeted antipsychotics (MARTAs)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Taichung Veterans General Hospital
Nausea, Vomiting
Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting
The goal of this clinical trial is to evaluate the efficacy and safety of olanzapine plus metoclopramide in preventing opioid-induced nausea and vomiting (OINV) in adult patients with advanced cancer who are initiating strong…
- Trial name
- NCT07208305
- Testing
- Olanzapine, Metoclopramide
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Affiliated Hospital of Qinghai University
Schizophrenia
Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)
The purpose of this study is to assess whether SCH 900435 (Org 25935) 16 mg twice daily is more effective than placebo in the treatment of patients with schizophrenia, using olanzapine 15 mg once daily as active control.
- Trial name
- GUEST (NCT00988728)
- Testing
- SCH 900435 (Org 25935), Olanzapine
- Sponsor
- Merck Sharp & Dohme LLC
Anorexia, Cachexia
Olanzapine for Cancer Related Anorexia-cachexia Syndrome
Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients. Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia.
- Trial name
- NCT06517199
- Testing
- Olanzapine 2.5 MG, Olanzapine 5 MG
- Where
- 2 sites in Thailand
- Volunteers
- 138 people
- Sponsor
- Mahidol University
Schizophrenia, Alzheimer's Disease
Side Effects of Newer Antipsychotics in Older Adults
This study will compare four atypical antipsychotic medications in terms of the risk of specific side effects each of them presents in middle-aged and elderly individuals.
- Conditions
- Schizophrenia, Alzheimer's Disease, Dementia
- Trial name
- NCT00245206
- Testing
- Aripiprazole, Olanzapine, Risperidone
- Where
- United States
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- Veterans Medical Research Foundation
Postoperative Nausea and Vomiting
Olanzapine for Nausea After Surgery
Ambulatory surgery is occurring with rapidly increasing frequency as surgical and anesthetic techniques have improved and pressure to reduce health-care costs has increased.
- Trial name
- NCT02755116
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Jaime B Hyman
Anorexia Nervosa, Bulimia Nervosa
Neurobiology of Eating Disorders Treatments
Background. Treatments of eating disorders result too often in partial psychological and physical remission, chronic course, dropout, relapse and death, with no fully known explanations for this failure.
- Trial name
- NEDT (NCT01990755)
- Testing
- CBT (Cognitive Behavioral Therapy), IBPP (individual psychology brief psychotherapy), CBT + OLANZAPINE
- Where
- Italy
- Volunteers
- 112 people
- Sponsor
- University of Turin, Italy
Breast Cancer
Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile
The objectives of this study are to determine if pharmacogenetic (PG) analysis of an individual enable optimal selection of antiemetic regimen for patients undergoing the first cycle of AC (Adriamycin + Cyclophosphamide) or FEC…
- Trial name
- NCT07455955
- Testing
- Standard antiemetic regimen or Olanzapine antiemetic regimen
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
Bipolar Disorder
Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness
The purpose of this study is to assess the efficacy and safety of continued combination therapy using Depakote plus olanzapine, vs.
- Trial name
- NCT00071253
- Testing
- Divalproex Sodium (Delayed-Release Tablets), Divalproex Sodium (Extended-Release Tablets), Olanzapine
- Where
- 15 sites in United States
- Volunteers
- 180 people
- Sponsor
- Abbott
Schizophrenia
Treatment for First-Episode Schizophrenia
This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
- Trial name
- NCT00000374
- Testing
- Olanzapine, Risperidone
- Where
- 2 sites in United States
- Volunteers
- 125 people
- Sponsor
- Northwell Health
Schizophrenia
Bifeprunox in the Treatment of Schizophrenia
Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia.
- Trial name
- NCT00193713
- Testing
- bifeprunox
- Sponsor
- Solvay Pharmaceuticals
Apathy, Schizophrenia
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
This study is looking to determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by AES-C-Apathy (Apathy Evaluation Scale - Clinician …
- Conditions
- Apathy, Schizophrenia, Schizophrenia; Psychosis
- Trial name
- NCT06482554
- Testing
- Lumateperone 42 mg, Risperidone 2 mg
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Louisiana State University Health Sciences Center Shreveport